RIGEL PRESENTS UPDATED DATA FROM THE ONGOING PHASE 1B STUDY EVALUATING R289 IN PATIENTS WITH LOWER-RISK MDS AT THE 67TH ASH ANNUAL MEETING AND EXPOSITION

Reuters · 1d ago

Please log in to view news